GlassScriptPhysician profile
Robi P Chatterji
NPI 1750322459
$4,127.11
in general payments reported to CMS, 2019-2025
31 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,108 · 2020: $672 · 2021: $1,026 · 2022: $611 · 2023: $336 · 2024: $111 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $701 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $701.44 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $607.58 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Merck Sharp & Dohme LLC | $451.96 | 2019-2023 | Segluromet, Steglatro, Steglujan |
| Astrazeneca Pharmaceuticals LP | $433.85 | 2019-2022 | |
| Amgen INC. | $413.83 | 2019-2025 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $337.36 | 2019-2022 | |
| Pfizer INC. | $312.89 | 2019-2024 | |
| Novo Nordisk INC | $277.37 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.89 | 2019-2023 | Jardiance |
| Sunovion Pharmaceuticals INC. | $150.02 | 2019-2020 | |
| Lilly USA, LLC | $148.33 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $109.71 | 2021 | |
| Novartis Pharmaceuticals Corporation | $88.20 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $54.38 | 2022 | |
| Lundbeck LLC | $49.61 | 2022 | |
| Supernus Pharmaceuticals, INC. | $46.81 | 2019 | Xyosted |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $44.80 | 2020-2022 | |
| Eisai INC. | $43.07 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $38.87 | 2025 | Austedo Xr |
| Xeris Pharmaceuticals, INC. | $32.09 | 2021-2022 | |
| Amarin Pharma, INC. | $28.85 | 2019 | |
| Mylan Specialty L.P. | $27.48 | 2019-2021 | |
| Halozyme INC | $18.85 | 2023 | |
| Avion Pharmaceuticals | $18.55 | 2023 | NP Thyroid 60 |
| Axsome Therapeutics, INC. | $17.92 | 2024 | Auvelity |
| Astellas Pharma US INC | $16.86 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.90 | 2024 | Voquezna |
| Dexcom, INC. | $15.83 | 2021 | |
| Medtronic, INC. | $13.53 | 2022 | |
| Esperion Therapeutics, INC. | $12.70 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.04 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robi Chatterji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.